Evidence map›Paper›PMID 41216048›Full record

ArticleCureus2025

The Cost of Lost Follow-Up: A Diagnosis of Sarcomatoid Lung Carcinoma Following a Presumed Benign Pulmonary Mass and the Necessity of a Physician's Suspicion.

Xochitl A Moreno Gonzalez, Peri G Mcclaskey, Michelle K Vu, Hamid Gogerdchian, Sanjana Murdande, Kevin T Dao, Alaleh Bazmi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xochitl A Moreno GonzalezInternal Medicine, University of California, Los Angeles (UCLA) Kern Medical, Bakersfield, USA.
Peri G McclaskeyInternal Medicine, University of California, Los Angeles (UCLA) Kern Medical, Bakersfield, USA.
Michelle K VuInternal Medicine, University of California, Los Angeles (UCLA) Kern Medical, Bakersfield, USA.
Hamid GogerdchianInternal Medicine, University of California, Los Angeles (UCLA) Kern Medical, Bakersfield, USA.
Sanjana MurdandeInternal Medicine, University of California, Los Angeles (UCLA) Kern Medical, Bakersfield, USA.
Kevin T DaoInternal Medicine, University of California, Los Angeles (UCLA) Kern Medical, Bakersfield, USA.
Alaleh BazmiInternal Medicine, University of California, Los Angeles (UCLA) Kern Medical, Bakersfield, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary sarcomatoid carcinoma is a rare non-small cell lung cancer that can rapidly progress and, unfortunately, serves as a diagnostic challenge. In many instances, patients can have non-specific symptoms, and the malignancy itself can produce negative biopsy results, leading to a false sense of security. This is especially true in larger tumors, since surrounding inflammation can obscure malignant tissue. As such, situations like these show the importance of a physician's clinical judgment in guiding management. Here, we would like to discuss a case where an asymptomatic 63-year-old man presented to the emergency department following a fall, but during the traumatic workup, an incidental lung mass was noted. Given the patient's lack of presenting hemoptysis, shortness of breath, unintentional weight loss, etc., with subsequent negative biopsy results, the patient was unconcerned regarding the pulmonary mass. Despite multiple attempts to contact the patient, he was lost to follow-up and returned with severe worsening of his malignancy. Thus, in this case report, we would like to discuss pulmonary sarcomatoid carcinoma, the methods of biopsy results, and the rate of false negatives, as well as highlight the importance of physicians' management and patient follow-up.

Indexed as

clinical managementfalse negativehigh clinical suspicionlost follow-uppulmonary masssarcomatoid lung carcinoma

Identifiers

PMID41216048
PMCPMC12596174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.